Skip to main content

H3N2 influenza hemagglutination inhibition method qualification with data driven statistical methods for human clinical trials.

Publication ,  Journal Article
Sawant, S; Gurley, SA; Overman, RG; Sharak, A; Mudrak, SV; Oguin, T; Sempowski, GD; Sarzotti-Kelsoe, M; Walter, EB; Xie, H; Pasetti, MF ...
Published in: Front Immunol
2023

INTRODUCTION: Hemagglutination inhibition (HAI) antibody titers to seasonal influenza strains are important surrogates for vaccine-elicited protection. However, HAI assays can be variable across labs, with low sensitivity across diverse viruses due to lack of standardization. Performing qualification of these assays on a strain specific level enables the precise and accurate quantification of HAI titers. Influenza A (H3N2) continues to be a predominant circulating subtype in most countries in Europe and North America since 1968 and is thus a focus of influenza vaccine research. METHODS: As a part of the National Institutes of Health (NIH)-funded Collaborative Influenza Vaccine Innovation Centers (CIVICs) program, we report on the identification of a robust assay design, rigorous statistical analysis, and complete qualification of an HAI assay using A/Texas/71/2017 as a representative H3N2 strain and guinea pig red blood cells and neuraminidase (NA) inhibitor oseltamivir to prevent NA-mediated agglutination. RESULTS: This qualified HAI assay is precise (calculated by the geometric coefficient of variation (GCV)) for intermediate precision and intra-operator variability, accurate calculated by relative error, perfectly linear (slope of -1, R-Square 1), robust (<25% GCV) and depicts high specificity and sensitivity. This HAI method was successfully qualified for another H3N2 influenza strain A/Singapore/INFIMH-16-0019/2016, meeting all pre-specified acceptance criteria. DISCUSSION: These results demonstrate that HAI qualification and data generation for new influenza strains can be achieved efficiently with minimal extra testing and development. We report on a qualified and adaptable influenza serology method and analysis strategy to measure quantifiable HAI titers to define correlates of vaccine mediated protection in human clinical trials.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Front Immunol

DOI

EISSN

1664-3224

Publication Date

2023

Volume

14

Start / End Page

1155880

Location

Switzerland

Related Subject Headings

  • United States
  • Influenza, Human
  • Influenza Vaccines
  • Influenza A Virus, H3N2 Subtype
  • Humans
  • Hemagglutination
  • Guinea Pigs
  • Antibodies, Viral
  • Animals
  • 3204 Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sawant, S., Gurley, S. A., Overman, R. G., Sharak, A., Mudrak, S. V., Oguin, T., … Tomaras, G. D. (2023). H3N2 influenza hemagglutination inhibition method qualification with data driven statistical methods for human clinical trials. Front Immunol, 14, 1155880. https://doi.org/10.3389/fimmu.2023.1155880
Sawant, Sheetal, Sarah Anne Gurley, R Glenn Overman, Angelina Sharak, Sarah V. Mudrak, Thomas Oguin, Gregory D. Sempowski, et al. “H3N2 influenza hemagglutination inhibition method qualification with data driven statistical methods for human clinical trials.Front Immunol 14 (2023): 1155880. https://doi.org/10.3389/fimmu.2023.1155880.
Sawant S, Gurley SA, Overman RG, Sharak A, Mudrak SV, Oguin T, et al. H3N2 influenza hemagglutination inhibition method qualification with data driven statistical methods for human clinical trials. Front Immunol. 2023;14:1155880.
Sawant, Sheetal, et al. “H3N2 influenza hemagglutination inhibition method qualification with data driven statistical methods for human clinical trials.Front Immunol, vol. 14, 2023, p. 1155880. Pubmed, doi:10.3389/fimmu.2023.1155880.
Sawant S, Gurley SA, Overman RG, Sharak A, Mudrak SV, Oguin T, Sempowski GD, Sarzotti-Kelsoe M, Walter EB, Xie H, Pasetti MF, Moody MA, Tomaras GD. H3N2 influenza hemagglutination inhibition method qualification with data driven statistical methods for human clinical trials. Front Immunol. 2023;14:1155880.

Published In

Front Immunol

DOI

EISSN

1664-3224

Publication Date

2023

Volume

14

Start / End Page

1155880

Location

Switzerland

Related Subject Headings

  • United States
  • Influenza, Human
  • Influenza Vaccines
  • Influenza A Virus, H3N2 Subtype
  • Humans
  • Hemagglutination
  • Guinea Pigs
  • Antibodies, Viral
  • Animals
  • 3204 Immunology